NCT00735904 - Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions

Carcinoma, Non-Small-Cell Lung (NSCLC)

Interventions

DRUG

AG-013736

AG-013736 5 mg tablets orally, twice daily, until disease progression

DRUG

gemcitabine

200-mg or 1 g lyophilized powder, to be administered as 1250 mg/m\^2 IV infusion on Day 1 and Day 8 of 21-day cycle. For a maximum of 6 cycles

DRUG

cisplatin

1mg/ml solution or as lyophilized powder, to be administered as 80 mg/m\^2 IV infusion on Day 1 of 21-day cycle. For a maximum of 6 cycles

Trial Locations (10)

Pfizer Investigational Site, Parktown

Pfizer Investigational Site, Dnipropetrovsk

Pfizer Investigational Site, Lviv

Pfizer Investigational Site, Donetsk

Pfizer Investigational Site, Cluj-Napoca

Pfizer Investigational Site, Oradea

Pfizer Investigational Site, Torun

Pfizer Investigational Site, Wodzislaw Sl.

Pfizer Investigational Site, Bucharest

Pfizer Investigational Site, Kyiv